Condition
Bacteria Infection
Total Trials
3
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
2Total
P 1 (1)
P 2 (1)
Trial Status
Recruiting1
Not Yet Recruiting1
Terminated1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07481539Phase 2RecruitingPrimary
Subcutaneous Piperacillin/Tazobactam Compared With Intravenous Treatment
NCT06666998Not Yet Recruiting
Real-World Pharmacokinetic/Pharmacodynamic Study of Eravacycline in Critically III Patients
NCT00599053Phase 1TerminatedPrimary
Early Versus Expectant Treatment of Ureaplasma Infection in Very Low Birth Weight Neonates
Showing all 3 trials